Role of neurohormonal modulators in heart failure with relatively preserved systolic function.
Cardiovascular disease remains the leading cause of mortality in the developed world. It is estimated that 5 million Americans suffer from heart failure (HF), and roughly 550,000 new cases are diagnosed annually. Studies have found that 40% to 71% of patients who have HF have relatively preserved systolic functions, or diastolic heart failure (DHF). Although there are abundant data to guide the treatment of heart failure and systolic dysfunction (systolic HF), evidence-based data are lacking in the management of DHF. This article examines the role of neurohormonal modulators in the management of DHF.
Rapp
Jonathan A
JA
Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
Gheorghiade
Mihai
M
D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage; D047228:Angiotensin II Type 1 Receptor Blockers / Q000008:administration & dosage; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage; D004334:Drug Administration Schedule; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D000451:Mineralocorticoid Receptor Antagonists / Q000008:administration & dosage; D018377:Neurotransmitter Agents; D013599:Systole
D000319:Adrenergic beta-Antagonists; D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000451:Mineralocorticoid Receptor Antagonists; D018377:Neurotransmitter Agents